<h1 id="angioedema">Angioedema</h1>
<p><strong>Definition</strong>: self-limited, asymmetric, localized, non-pitting swelling</p>
<p><strong>Background</strong></p>
<ul>
<li>15% of population</li>
<li>50% with urticaria</li>
<li><em>Common sites:</em> perioribtal, lips, tongue, extremity, bowel wall</li>
<li><em>Main cause of death:</em> Laryngeal edema (25-40% mortality if present)</li>
</ul>
<h2 id="syndromes-and-specific-treatments">Syndromes and Specific Treatments</h2>
<p><strong>Idiopathic Angioedema</strong></p>
<ul>
<li>38% of patients with angioedema</li>
</ul>
<p><strong>Allergic or IgE Mediated Angioedema</strong></p>
<ul>
<li>Type I hypersensitivity reaction</li>
<li>Commonly from food or medications</li>
<li><em>Tx:</em> allergen avoidance, antihistamine, H2 blockers, glucocorticoid, epinephrine for laryngeal edema</li>
</ul>
<p><strong>Hereditary Angioedema</strong></p>
<ul>
<li>C1q esterase inhibitor deficiency</li>
<li><em>Triggers:</em> trauma (especially dental trauma), anxiety, menstruation, infection, exercise, alcohol consumption, stress</li>
<li><em>Prophylaxis tx:</em> <strong>danazol</strong> better than tranexamic acid and aminocaproic acid</li>
<li><em>Acute tx:</em>  <strong>FFP</strong> (or C1 inhibitor concentrate - given in Europe/Canada only)</li>
<li>Usual IgE-mediated treatment regimen ineffective except epinephrine for laryngeal edema</li>
</ul>
<p><strong>ACE Inhibitor Angioedema</strong></p>
<ul>
<li>Up to 2.2% of those taking ACE-I&#39;s</li>
<li>From elevated levels of bradykinin</li>
<li>Highest incidence during 1st month of starting medication, but can occur years after </li>
<li>5x more common in African-Americans compared to Caucasians</li>
<li>Controversial whether patient can take ARBs (doesn’t cause elevated bradykinin) as well – some with angioedema.</li>
<li><em>Tx: </em> discontinue medication and supportive care</li>
<li>Usual IgE-mediated treatment regimen ineffective except epinephrine for laryngeal edema</li>
</ul>
<p><strong>Treatment philosophy:</strong> </p>
<ul>
<li>Low threshold to protect airway by intubation</li>
<li><strong><em>Pearl:</em></strong> Be sure to prescribe patients Epi-pen if discharged home</li>
<li><em>Fiberoptic nasopharyngoscopy</em>: consider performing on all patients with voice change to look for largnyeal edema</li>
</ul>
<h2 id="admission-guidelines-for-angioedema">Admission guidelines for angioedema</h2>
<p>(<a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18374684">Ishoo et al., Head Neck Surg, 1999</a>)  </p>
<ul>
<li>93 episodes in 80 patients (1985-95) with no deaths </li>
<li>9.7% cases required intubation/tracheostomy</li>
<li><em>Causes:</em> 39% from <span class="drug">ACE-I</span></li>
<li><em>Disposition:</em> 25% outpt, 23% floor, 53% ICU</li>
<li>ICU admissions correlated with voice change, hoarseness, dyspnea, rash </li>
<li>Airway intervention correlated with voice change, hoarseness, dyspnea, stridor</li>
</ul>
<p><strong>Proposed staging system:</strong></p>
<ul>
<li><strong>Stage I:</strong> Facial rash, facial edema, lip edema - outpatient</li>
<li><strong>Stage II</strong>: Soft palate edema – outpatient or floor</li>
<li><strong>Stage III:</strong> Lingual edema --&gt; ICU (7% required airway intervention)</li>
<li><strong>Stage IV:</strong> Laryngeal edema –&gt; ICU (24% required airway intervention)</li>
</ul>
<h2 id="references">References</h2>
<ul>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18374684">Ishoo E et al. Predicting airway risk in angioedema: Staging system based on presentation. Otolaryngol Head Neck Surg 1999; 121:263-8.</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18374684">Temino VM, Peebles RS. Spectrum and Treatment of Angioedema. Am J Med 2008; 121: 282-6</a></li>
<li><a href="http://emedicine.medscape.com/">Emedicine.com</a></li>
</ul>
